- CEO Joe Jimenez' review of the viability of Novartis' (NVS) small divisions will probably mean that at least one will eventually be sold.
- Three units: animal health, vaccines and OTC medicines won't globally scale so it the best solution for shareholders may be to get rid of them.
- He cites the unattractive reimbursement environment as the main challenge for the businesses.
Are you Bullish or Bearish on ?
Results for ()
Thanks for sharing your thoughts.
From other sites
at Zacks.com (Thu, 3:19PM)
at Nasdaq.com (Fri, 9:00AM)
at Zacks.com (Feb 24, 2015)
at Investor's Business Daily (Feb 23, 2015)
at Benzinga.com (Feb 23, 2015)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs